Development and production of APIs

Razvoj in proizvodnja zdravilnih učinkovin

We pay special attention to APIs used in our medicinal products. For the most part, we develop and manufacture APIs ourselves. This process includes developing synthesis procedures, optimising technological procedures, and transferring to production scale. Supervision over manufacturing operations, safety and quality of APIs is of utmost importance to us. This reduces our dependence on external suppliers.

The synthesis of our APIs takes place over several extremely complex reaction stages. Each stage is under stringent control. An API is formed under optimal reaction conditions using chemical transformation of two or more substances (chemical compounds, intermediates). We use innovative solutions to overcome patent restrictions.

We use our own synthesis procedures and cleaning technologies to ensure our APIs are of ultra-high purity. Using the most sensitive analytical techniques, we ensure the absence of critical impurities and compliance with the highest quality standards.

APIs manufactured,

using our procedures are high-quality, safe, and efficient. We guarantee that based on data obtained during chemical synthesis development and in several controls performed during the preparation process.

We evaluate the impact of individual factors on chemical reactions through different analytical techniques. These play a key role in the development of chemical synthesis and the transfer of processes to a larger scale. We determine the in-process controls for chemical synthesis during production based on these data.

Krka’s APIs are used in our flagship finished products, which include all medicinal products containing valsartan, perindopril, losartan, atorvastatin, esomeprazole, pantoprazole, and clopidogrel.

Continue browsing

Multiparty banner 1


This is a one-stop source of information about Krka shares and dividends as well as answers to frequently asked questions.



We are continually consolidating our position as one of the leading generic pharmaceutical companies in the world.



We stand shoulder to shoulder to foster an environment that is built on mutual trust, respect, cooperation, lifelong learning and a responsible attitude towards the work we do.